- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03984331
Fish Skin Compared to Cadaver Skin as Temporary Cover for Full Thickness Burns (Kereburn)
MariGen Fish Skin Compared to Cadaver Skin as a Temporary Covering for Full Thickness Burns: An Early Feasibility Trial
Objectives and rationale: Optimal burn management involves removing all the dead or burned tissue as early as feasible and cover with an autograft called split thickness skin graft (STSG) taken from the patient. This procedure creates a new wound on the patient and sometimes, when the burn covers very large portion of the patient body, there is a lack of healthy skin to use for this purpose. Under those circumstances, donated cadaver skin is used as a temporary coverage until the patient´s own donor site wound has healed enough to be used again.
The proposed clinical study aims to determine if treatment with fish skin is an alternative to cadaver skin as a temporary coverage for debrided full-thickness burns prior to STSG in terms of autograft take, time to heal, quality of healing (scarring), pain and adverse effects.
Study Overview
Detailed Description
Mortality after severe burns has diminished during the last decades and survival is no longer considered the primary end point of care. More attention is paid to the final functional and cosmetic outcome of the affected area but outcomes are still far from optimal. For the time being, one of the main goals in burn treatment is to achieve reduced scar formation from the time of injury. A temporary or permanent covering of the wound bed should be achieved at the time of excision. In burn wounds the gold standard is to use split thickness skin graft, or STSG, which includes epidermis, basement membrane, and a part of upper dermis. Yet the use of skin grafts has many shortcomings: there is only a limited amount of skin available for grafting, the donor sites are susceptible to infections, to pain, to pigmentation changes, and to scarring especially when re harvested. Therefore, for complicated burns, initial treatment is often with temporary coverage where cadaver skin has been the accepted standard of care.
In recent years there has been progress in the development of advanced wound care products. This has resulted in a third generation of wound treatment, known as acellular dermal grafts or skin substitutes.
Aims The goal of this clinical trial is to demonstrate that fish skin is an alternative to cadaver skin as early cover before STSG in burn wounds. This trial will be open to patients who are scheduled to receive meshed STSG of any ratio. Fish skin or cadaver skin will be applied after initial debridement in order to prepare the wound area for STSG.
5 to 10 patients will be prospectively enrolled and two burn sites on their body will randomized to initial treatment after debridement with either fish skin or cadaver skin for 7+/-3 days. After the initial treatment, the test sites will be grafted with STSG.
The histological differences and the functional outcomes will be assessed for 12 months.
Products will be applied by experienced burn surgeons at a burn center. At approximately Day 7, or when the treating physician deems the wound to be ready for grafting, the products will be removed. Prior to grafting, a second blinded burn surgeon will assess the burn wound bed.
Important dates for blinding are on Day 7 prior to STSG treatment and on Days 14, 21 and 28 for graft take, epithelialisation and wound closure. Scar assessment at 3 and 12 months via the Vancouver Scar Sale will also be fully blinded.
Key interventions:
Randomized to either cadaver skin or fish skin after initial debridement Two areas each of 10-20 x 7 cm side by side. Other areas will be treated as per local Standard of care (SOC). Concomitant medications will be given, e.g. painkiller, antibiotics, as needed.
Wound dressings changed approximately every three days until allograft or xenograft removal.
Approximately one week after placement the fish skin and cadaver allografts removed as required.
Subsequent meshed autograft placement if donor sites are available. Autografts covered with secondary antimicrobial/silver dressing and dressings approximately every 3 days until healed.
Autografts monitored for adherence, color, autograft take, and visual signs of infection.
During the operation, a 3 or 4 mm punch biopsy will be harvested from the excised wound bed before covering with any material.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Burn Center at Medstar Washington Hospital Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Participant or legally authorized representative is willing and able to give informed consent for participation in the clinical trial.
- Patients from 22 to 75 years of age. Acute full thickness burn wounds outside the following areas; facial, genital and across joints, requiring widely meshed skin grafting or staging of STSG treatment due to insufficient healthy donor sites.
- Maximal Total Body Surface Area (TBSA) of 50% full thickness burns
- Able (in the Investigators opinion) and willing to comply with all clinical trial requirements.
- Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the clinical trial.
Exclusion Criteria:
Declined consent
- Immunocompromised patients or patients receiving immunosuppressive therapy
- Presently participating in another clinical trial
- Patient actively taking glucocorticoid or cytostatic medications
- Persons with immune deficiency because of disease or iatrogenic-
- Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the clinical trial, or may influence the result of the clinical trial, or the participant's ability to participate in the clinical trial.
- Patient has known allergy to fish. (Shell fish allergy is not a contraindication)
- Exclusion areas are, facial, genital and across joints.
- Female participants who are pregnant, breast feeding or planning pregnancy during the course of the clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fish skin
All patients will receive both treatments, fish skin and cadaver skin, as early cover after early debridement.
This group of wounds will receive only fish skin.
|
One out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive fish skin as early cover.
Each patient thus serves as his/her own control.
After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft.
Other Names:
|
Active Comparator: Cadaver skin
All patients will receive both treatments, fish skin and cadaver skin, as early cover after early debridement.
This group of wounds will receive only cadaver skin.
|
One out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive cadaver skin as early cover.
Each patient thus serves as his/her own control.
After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportions of wounds that have healed
Time Frame: At 3 weeks days after STSG
|
Wounds which have reached at least 95% epithelialization
|
At 3 weeks days after STSG
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of wound area exhibiting graft failure
Time Frame: At 2 weeks after STSG
|
The proportion of the wound area in which the graft does not take
|
At 2 weeks after STSG
|
Full epithelialization of wound
Time Frame: At 2 weeks after STSG
|
Number of wounds fully epithelialized
|
At 2 weeks after STSG
|
Scarring estimated with the Vancouver Scar Scale (VSS)
Time Frame: At 12 months after STSG
|
Vascularity (0-3), pigmentation (0-3), pliability (0-3), height (0-3), Total score;0=Best, 12=worst
|
At 12 months after STSG
|
Inflammation profiling of wound punch biopsies as assessed by histology
Time Frame: Before STSG, 2 and 3 weeks and 12 months after STSG
|
Histological analysis of punch wound biopsies via standard H&E staining, or staining for known inflammatory markers (TNF-alpha, IL-1b, IL-6, IL-8)
|
Before STSG, 2 and 3 weeks and 12 months after STSG
|
Average number of antibiotics treatments per patient
Time Frame: At all treatments appointments until 4 weeks after STSG
|
Average number of antibiotics treatments per patient
|
At all treatments appointments until 4 weeks after STSG
|
Pain assessed by the Visual Analog Scale (VAS) before and after dressing changes
Time Frame: At all treatments appointments until 3 weeks after STSG
|
Pain by the Visual Analog Scale (VAS) on a scale of 0-10, 0=no pain, 10= pain as bad as it could be
|
At all treatments appointments until 3 weeks after STSG
|
Bleeding time
Time Frame: At all treatments appointments until 3 weeks after STSG
|
Average time in seconds to achieve hemostasis during dressing changes
|
At all treatments appointments until 3 weeks after STSG
|
Dermatitis
Time Frame: At all treatments appointments until 3 weeks after STSG
|
Incidence of dermatitis
|
At all treatments appointments until 3 weeks after STSG
|
Ease-of-use
Time Frame: Day 0 when grafts are initially applied after debridement
|
Ease-of-use as judged by attending physician on a VAS scale of 0=extremely difficult to use to 10=Very easy to use
|
Day 0 when grafts are initially applied after debridement
|
Incidence of hematoma
Time Frame: At all treatments appointments until 3 weeks after STSG
|
Nr of wounds which develop a hematoma
|
At all treatments appointments until 3 weeks after STSG
|
Inflammatory profiling of wound punch biopsies as assessed by mass spectrometry
Time Frame: Before STSG, 2 and 3 weeks and 12 months after STSG
|
Mass spectrometry analysis of punch wound biopsies, investigating known inflammatory markers (TNF-alpha, IL-1b, IL-6, IL-8)
|
Before STSG, 2 and 3 weeks and 12 months after STSG
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jeffrey W. Shupp, MD, MedStar Washington Hospital Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KS-0340 - P2587
- CDMRP-MB150220 (Other Grant/Funding Number: MBRP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Burns
-
MediWound LtdUnknownBurns, Upper Extremity | Burns, Lower ExtremitySlovakia
-
Singapore General HospitalUnknownAcute Thermal BurnsSingapore
-
American Scitech InternationalJohnson & JohnsonUnknownBurns | Electric BurnsUnited States
-
RenovaCare, IncActive, not recruitingBurns | Burns Second Degree | Burns Deep Second DegreeUnited States
-
MediWound LtdCompletedThermal BurnsUnited States, Israel, Belgium, Czechia, Georgia, Germany, Italy, Romania
-
Sun Yat-sen UniversityCompleted
-
MediWound LtdActive, not recruitingThermal BurnsUnited States, United Kingdom, Spain, Georgia, Belgium, Poland, Germany, Hungary, India, Italy, Netherlands, Romania, Slovakia, Ukraine
-
Virginia Commonwealth UniversityNot yet recruiting
-
The Hong Kong Polytechnic UniversityCompleted
-
St. Justine's HospitalRecruiting
Clinical Trials on Fish skin
-
Kerecis Ltd.Tufts University School of Dental MedicineCompletedMucogingival Deformity - Insufficient Keratinized Tissue
-
University of BergenBergen Medical Research Foundation; Skretting ASA; Leroy Seafood Group ASACompletedObesity | OverweightNorway
-
Nucleo De Pesquisa E Desenvolvimento De Medicamentos...Completed
-
Assiut UniversitySouth Egypt Cancer InstituteCompletedAcute Myeloid LeukemiaEgypt
-
University of CopenhagenAnjo A/SCompletedObesity | Cardiovascular Disease | Metabolic Syndrome | Growth | Blood Pressure
-
University of Texas Southwestern Medical CenterUniversity of Massachusetts, WorcesterCompleted
-
University of BergenBergen Medical Research Foundation; Skretting ASA; Leroy Seafood Group ASACompletedObesity | Metabolic DisordersNorway
-
University of CopenhagenCompletedQuality of Life | Cancer Cachexia | Side EffectsDenmark
-
National Institute of Diabetes and Digestive and...Completed
-
Harvard School of Public Health (HSPH)Completed